- Open Access
Correlative study between C-reactive protein, clinical severity, and nerve conduction studies in Guillain-Barrè syndrome
© The Author(s) 2018
Received: 29 September 2017
Accepted: 23 March 2018
Published: 25 April 2018
Guillain-Barre' syndrome (GBS) is a serious autoimmune disorder in which the immune system attacks healthy nerve cells of the peripheral nervous system causing polyradiculoneuropathy which leads to weakness, numbness, and tingling, and can eventually cause paralysis. Autoimmune conditions like GBS can induce a high level of inflammation resulting in an increase in the C-reactive protein( CRP) production. The aim of this study is to assess the relationship between CRP level and the clinical severity as well as the electrophysiological findings of nerve conduction studies in patients with GBS.
Twenty- four patients (10 males &14 females) with ages ranged from 14 to 50 years and a mean age of 33.46 ±12.25 years who fulfilled the clinical criteria for diagnosing GBS were recruited within the first 2 weeks of onset of illness, in a cross- section study. They underwent general and neurological examination. Nerve conduction studies as well as assessment of serum CRP level were done.
There was a statistically significant positive correlation between clinical severity assessed by (Hughes disability scale) and serum CRP level in GBS patients. Multivariate logistic regression analysis showed that both gastroenteritis, cranio-bulbar affection, need for mechanical ventilation (MV), disability score >4, and absent motor and sensory responses were significantly associated with high serum CRP level >6mg/dl.
The results of this study support the hypothesis that in GBS patients, gastroenteritis, craniobulbar affection, need for MV, disability score >4, and absent motor and sensory nerve responses were significantly related to high serum CRP level. This reflects the negative impact of the inflammatory response elicited by high CRP level on clinical severity in GBS patients, and so it may be used as a prognostic marker of clinical severity of GBS and this can help in therapeutic decision making.
Guillain-Barré syndrome (GBS) is a severe autoimmune disorder in which the immune system forms auto-antibodies against healthy nerve cells of the peripheral nervous system causing polyradiculoneuropathy which in turn causes weakness, numbness, and tingling and can eventually cause paralysis. The cause of this condition is unknown, but it is typically triggered by many infectious illnesses like gastroenteritis and respiratory tract infection (Yuki and Hartung 2012). It is generally precipitated 1–3 weeks following many infections like respiratory tract infection and Campylobacter jejuni infection which suggest an underlying humoral immunopathogenic mechanism (Yu et al. 2006).
C-reactive protein (CRP) is an acute phase reactant produced by the liver in response to factors released by macrophages and adipocytes. Its level rises dramatically during inflammatory processes occurring in the body, and it is a critical component of the immune response (Lau et al. 2005), Moreover, CRP plays an important role in innate immunity as an early defense system against infections and its level rises when there is a microbial infection or an inflammation without microbes (Peaceman et al. 1997). Autoimmune conditions like GBS can stimulate the production of a high level of inflammation resulting in an increase in the CRP production, so highly sensitive CRP assay may become a new risk assessment marker in the future for autoimmune disorders including GBS (Vaishnavi et al. 2014). In addition, measuring CRP levels can help to screen both infections and inflammatory diseases; also, dynamic serial measurement of CRP has been widely used to help therapeutic decision making (Lobo 2012).
Electrophysiology including nerve conduction study (NCS) plays a determinant role in GBS diagnosis and classification of the subtypes and in establishing prognosis (Uncini and Kuwabara 2012). Diagnostic sets have been proposed for assessment of acute inflammatory demyelinating neuropathy (AIDP), acute motor axonal neuropathy (AMAN), and acute motor and sensory axonal neuropathy (AMSAN). Nerve conduction studies should be repeated for proper diagnosis of GBS subtypes, identification of pathophysiological mechanisms, and hence assessment of prognosis (Uncini and Kuwabara 2012).
Aim of the study
This study was done to assess the relation between serum CRP level and the clinical severity as well as the electrophysiological findings of nerve conduction studies in patients with GBS.
A cross-sectional study was conducted in the Neurology Department, Zagazig University Hospitals during the period from February 2015 to July 2016. Twenty-four patients (10 males, 14 females) which fulfilled the clinical criteria for diagnosis of GBS according to Asbury and Cornblath (1990) were recruited in the study. Their ages ranged from 14 to 50 years with a mean age 33.46 ± 12.25 years.
- (a)Features required for diagnosis:
* Progressive weakness in both arms and legs (might start with weakness only in the legs)
* Areflexia (or decreased tendon reflexes)
- (b)Features that strongly support diagnosis:
* Progression of symptoms over days to 4 weeks
* Relative symmetry of symptoms
* Mild sensory symptoms or signs
* Cranial nerve involvement, especially bilateral weakness of facial muscles
Any other neurological illness whether acute or chronic
Any other causes which can affect NCSs, e.g., drugs, toxins, diabetes mellitus (DM)
Concomitant inflammatory disease whether infectious or non-infectious, within the last 2 weeks
Tumors, metastases, and immunomodulatory therapy within the last 6 months
History of surgery or significant trauma within the last 2 weeks
Patients with system failure (respiratory, hepatic, renal, cardiac)
Severe psychiatric illness
A healthy state
Minor symptoms and capable of running
Able to walk 10 m or more without assistance but unable to run
Able to walk 10 m across an open space with help
Bedridden or chair bound
Requiring ventilation for at least part of the day
Complete history taking stressing on the onset, course, and duration of the disease. Also, history of previous gastroenteritis or upper respiratory tract infection
Complete general examination
Neurological examination including assessment of clinical GBS severity using a disability scale adapted from Hughes and Rees (1997)
GBS disability scale (Hughes and Rees 1997)
ECG to detect any concomitant arrhythmias
Laboratory investigations include the following:
- (a)Routine investigations:
* Complete blood count (CBC)
* Erythrocyte sedimentation rate (ESR)
* Blood glucose level
* Liver function tests (LFT) and kidney function test (KFT)
Quantitative assessment of serum CRP using latex: within 2 weeks of symptom onset. CRP-Turbilatex is a quantitative turbidimetric test for the measurement of CRP in human serum or plasma. Latex particles coated with specific human anti-CRP are agglutinated when mixed with samples containing CRP. The agglutination causes an absorbance change, dependent upon the CRP contents of the patient sample that can be quantified by comparison from a calibrator of known CRP concentration. Normal concentration in healthy human serum is usually lower than 10 mg/l, slightly increasing with aging. Higher levels are found in late pregnant women, mild inflammation and viral infections (10–40 mg/l), active inflammation, bacterial infection (40–200 mg/l), severe bacterial infection, and burns (> 200 mg/l) (Clyne and Olshaker 1999).
Nerve conduction study:
Nerve conduction studies (NCSs) were done with an EMG machine (Nemus, Biomedica, Model number 00655, Galileo NT software version 3.71/00, Italy) within 2 weeks of onset of symptoms.
* Motor NCS for median, ulnar, common peroneal, and posterior tibial nerves
* Sensory NCS for median, ulnar, sural, and superficial peroneal nerves were recorded antidromically with surface ring (median and ulnar nerves) and disc (sural and superficial peroneal nerves) electrodes
* Late response: F-waves were recorded following at least 10 distal stimuli to determine minimal F-wave latency or F-wave absence
* Distal latency (DL), compound motor action potential (CMAP) amplitude, and conduction velocity (CV) of motor and sensory nerves
* Peak sensory latency, sensory nerve action potential amplitude (SNAP)
* F-wave (latency and persistence)
Demyelinating polyradiculoneuropathy consistent with GBS if there were a combination of prolonged distal motor latency (> 150% of the upper limit of normal), CV (< 70% of the lower limit of normal), and prolongation of F-wave latency (> 150% of the upper limit of normal)
Axonal polyradiculoneuropathy if there was low CMAP amplitude, normal conduction velocity or slightly slowed, and normal distal latency or slightly prolonged
The values for each variable were compared with the standard ranges of normality.
This is the grant number for ethics approval (IRB#: 1879-15-2-2015). A written informed consent was obtained from every patient or his/her relative to be included in the study. This study was approved by the institute research board of Faculty of Medicine, Zagazig University.
The obtained data were tabulated and analyzed using Statistical Package of Social Science (SPSS version, 22) (Levesque 2007). Continuous variables were expressed as mean ± SD (standard deviation) and median. The means were compared with independent Student’s t test. Categorical variables were compared using the chi-square test. Correlation coefficient (Spearman’s or Pearson’s) was calculated to assess the relation between serum CRP levels and clinical severity of GBS using Hughes disability scale. Odds ratio (ORs) and confidence intervals (CIs) were also calculated in a logistic regression model to assess the independent factors that affect prognosis of GBS. A difference was considered statistically significant if P value was ≤ 0.05.
A total of 24 GBS cases with ages ranged from 14 to 50 years (mean age 33.46 ± 12.25 years) were included in this cross-sectional study according to the above mentioned inclusion and exclusion criteria.
Demographic data and clinical presentation in the studied GBS cases
(N = 24)
Mean ± SD
33.46 ± 12.25
Cranial nerve involvement
Mean serum CRP level (mg/dl) in the studied GBS cases
Mean serum CRP level ± (SD)
(N = 24)
Mean ± SD
5.52 ± 4.57
Cutoff point of CRP level
≤ 6 mg/dl
> 6 mg/dl
Types of electrophysiological findings of the studied GBS cases
(N = 24)
Motor and sensory nerve conduction study findings in GBS cases
(N = 24)
Motor nerve conduction study
Absent motor response
Prolonged distal latency
Low CMAP amplitude
Sensory nerve conduction study
Reduced SNAP amplitude
Relation between Hughes disability scale score and mean serum CRP level among the studied GBS patients
Disability score (Hughes disability scale)
CRP (mg/dl) X ± SD
3.33 ± 1.74
5.75 ± 3.58
8.45 ± 5.3
11.3 ± 8
Multivariate regression analysis for significant findings in GBS patients with serum CRP > 6 mg/dl
Positive craniobulbar manifestation
Need for MV
Disability score > 4
Absent motor response
Low CMAP amplitude
Absent sensory response
Guillain-Barré syndrome is a clinically diagnosed disorder, but nerve conduction studies can help to support the diagnosis and discriminate between axonal and demyelinating subtypes and could relate to prognosis (Chiò et al. 2003). C-reactive protein (CRP) is one of acute phase proteins, the serum or plasma levels of which rise during general non-specific response to a wide variety of diseases, either infectious or inflammatory including autoimmune diseases (Lau et al. 2005).
Several studies agree that GBS can occur at any age (Hughes and Rees 1997). In the present study, the mean age of GBS patients was 33.46 (±12.25) years. Our results were in accordance with that obtained by Mohamed et al. (2016), where the mean age of their patients was 38.74 years. However, a higher mean age of 43.7 years was reported by González-Suárez et al. (2013).
Concerning sex distribution, it was reported that GBS was more frequent in females (58.3% females vs 41.7% males) in our study. Other studies found that GBS was more common in male patients (Hughes and Cornblath 2005; Sejvar et al. 2011; Dhadke et al. 2013; Fokke et al. 2014). However, González-Suárezand et al. (2013) in their study found no significant difference between both genders among GBS patients.
Regarding preceding infections in our study, it was found that about 41.7% had gastroenteritis and 25% had URTI while only 33.3% had no history of any infection prior to presentation. These data were in agreement with results obtained by Newswanger and Warren (2004) who identified C. jejuni as the most frequent antecedent pathogen of GBS. Sudulguntaand et al. (2015) in their study found that the most common antecedent events associated with GBS was gastrointestinal infection (47.25%) followed by fever and cough which represented 42.62%, while upper respiratory tract infection was reported to be the most common preceding infection in studies done by Chiò et al. (2003) and Willison (2005).
Patients with Guillain-Barré syndrome differ from each other regarding the degree as well as distribution of motor and sensory symptoms plus the presence of cranial nerve deficits, autonomic dysfunction, and preceding infection. Regarding the clinical presentation, we found that all patients (100%) had both motor and sensory symptoms, while 54.2% had facial nerve involvement, 16.7% had autonomic symptoms, and 16.7% needed MV. Fokke et al. (2014) and Kalita and Misra (2014) reported that motor weakness was the most frequent symptom (73.8–100%) and sensory symptoms represented 52.7% and cranial nerve affection represented 53–62.5%. Other studies (Dhadke et al. 2013; Fokke et al. 2014; Kalita and Misra 2014) found that dysautonomia represented 20.4% and MV was found in 13.1–28%. A low frequency of sensory manifestations (32.5%) was recorded by Dhadke et al. (2013).
The Hughes disability scale was used to assess clinical severity of GBS in our study. 16.7% of our patients were able to walk either without assistance or with help (grades 2 and 3). The majority of our patients (62.5%) were bedridden or chair bound (grade 4) and 12.5% needed mechanical ventilation (grade 5). This was in agreement with data obtained by Parmar et al. (2013) who reported that the majority of their GBS patients were in grade 4 (83.7%). The author explained that the reason for the high frequency of severe disability was the delay in seeking treatment.
Regarding the electrophysiological studies in our GBS patients, we found that mixed axonal and demyelinating polyneuropathy was the most common type (45.8%) followed by demyelinating polyneuropathy (29.2%) and axonal polyneuropathy (8.3%). In accordance with our result, Walling and Dickson (2013) found that multifocal demyelinating polyneuropathy with secondary axonal degeneration was the most common subtype. However, other studies found that demyelinating polyneuropathy was the predominant subtype followed by demyelinating and axonal polyneuropathy (Fokke et al. 2014; Parmar et al. 2013). This variability of subtypes of GBS among countries could be due to different genetic background and environmental exposures (Parmar et al. 2013).
As regards electrophysiological findings of NCSs among our patients, it was also found that F-wave abnormality was the most common finding (70.8%), then prolonged distal latency (DL) (66.7%), low compound motor action potential (CMAP) amplitude (54.2%), and slow conduction velocity (37.5%), and the least was absent motor response (20%). Whereas in sensory nerve conduction studies, prolonged latency as well as reduced SNAP amplitude were the most prominent finding (16.7%). Our results were in agreement with that of Parmar et al. (2013) who found that the most common electrodiagnostic abnormalities were absent or prolonged F-wave (90%), prolonged DL (80%), delayed CV (73%), partial or complete conduction block (63%), reduced CMAP amplitude (38%), and abnormal SNAP (28%). The authors explained the predominance of F-wave abnormalities in GBS patients by an axonal dysfunction in proximal nerve segment or by axonal degeneration at the level of nerve root (Parmar et al. 2013).
C-reactive protein is one of the acute-phase proteins, which rises during a wide range of acute and chronic inflammation (Vaishnavi et al. 2014). Also, CRP has a role in autoimmune diseases as it can bind to auto-antigens; thus, immune-mediated conditions like GBS can stimulate inflammatory response which in turn lead to in an increase in CRP level (Szalai 2004). In the present study, CRP level > 6 mg/dl were found in 33.5% of our patients. This was in agreement with Vaishnavi et al. (2014) who found that 24.4% of their patients were positive for CRP. Although there were few studies concerning CRP serum levels in patients with GBS, a high level of CRP was reported in other studies (Daniel 2011; Chen et al. 2013).
On doing a multivariate regression analysis, it was found that serum CRP level > 6 mg/dl was significantly associated with preceding infection (gastroenteritis), need for MV, disability score > 4, and absent both motor and sensory nerve responses. Our results were in agreement with the study done by Rajabally and Uncini (2012) who found that predictors of bad prognosis were higher GBS disability score at 2 weeks, preceding diarrheal illness, faciobulbar palsy, need for MV, low CMAP amplitude, and absent motor responses. Also, Ortiz-Corredor et al. (2007) studied motor recovery after GBS in childhood, using univariate analysis and found that cranial nerve impairment, requirement of assisted ventilation, presence of quadriplegia, and presence of non-excitable motor nerves were associated with delayed motor recovery time. In explanation for that significant association, Vaishnavi et al. (2014) postulated that autoimmune conditions like GBS can stimulate inflammatory response and hence result in an increase in CRP production which in turn significantly related to clinical severity and severe disability resulting in poor prognosis in GBS patients.
The results of the current study support the hypothesis that in GBS patients, history of preceding gastroenteritis, craniobulbar affection, need for MV, disability score > 4, and absent motor and sensory nerve responses were significantly associated with high serum CRP level, reflecting the negative impact of the inflammatory response on clinical severity and prognosis. Serial measurement of CRP can be used as risk assessment and prognostic marker.
The study had some limitations as small sample size, and the study was a cross-sectional one.
This study received no funding from any public, commercial, or not-for profit sectors.
YAA participated in sequence alignment and revision of the manuscript. SAA conceived the study and participated in its design and coordination. HAF did the statistical analysis and participated in the study design and coordination and final revision of the manuscript. SA is responsible for the collection of patients’ data and writing the methodology of the study. All authors read and approved the final manuscript.
Ethics approval and consent to participate
A written informed consent was obtained from every patient or his/her relative to be included in the study. This study was approved by the institute research board of Faculty of Medicine, Zagazig University.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
- Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol. 1990;27:21–4.View ArticleGoogle Scholar
- Chen AC, Chen CM, Chang HR, Yeo KJ, Tsao SM, Hsiao PC, Tsai SJ. Complicated acute motor axonal neuropathy with delayed acute respiratory distress syndrome and rapidly progressive glomerulonephritis: a case report. Acta Neurol Taiwanica. 2013;22(1):26–31.Google Scholar
- Chiò A, Cocito D, Leone M, Giordana MT, Mora G, Mutani R. Guillain–Barré syndrome: a prospective, population based incidence and outcome survey. Neurology. 2003;60:1146–50.View ArticlePubMedGoogle Scholar
- Clyne B, Olshaker JS. The C-reactive protein. J Emerg Med. 1999;17(6):1019–25.View ArticlePubMedGoogle Scholar
- Daniel S. Guillain Barré syndrome: Anaethesia tutorial of the week 238. ATOTW. 2011;238:2–8.Google Scholar
- Dhadke SV, Dhadke VN, Bangar SS, Korade MB. Clinical profile of Guillain Barre syndrome. J Assoc Physicians India. 2013;61:168–72.PubMedGoogle Scholar
- Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014;137:33–43.View ArticlePubMedGoogle Scholar
- González-Suárez I, Sanz-Gallego I, Arpa J. Guillain-Barré syndrome: natural history and prognostic factors: a retrospective review of 106 cases. BMC Neurol. 2013;13:95.View ArticlePubMedPubMed CentralGoogle Scholar
- Gordon P, Willbourn AJ. Early electrodiagnostic findings in Guillain. Arch Neurol. 2001;58:913–7.View ArticlePubMedGoogle Scholar
- Hughes RA, Cornblath DR. Guillain–Barré syndrome. Lancet. 2005;366:1653–66.View ArticlePubMedGoogle Scholar
- Hughes RA, Rees JH. Clinical and epidemiologic features of Guillain-Barré syndrome. J Infect Dis. 1997;176(2):92–9.View ArticleGoogle Scholar
- Kalita J, Misra UK. Guillain-Barré syndrome: subtypes and predictors of outcome from India. JPNS. 2014;19:36–43.View ArticlePubMedGoogle Scholar
- Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines. Molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol. 2005;288:2031–41.View ArticleGoogle Scholar
- Levesque R. SPSS programming and data management: a guide for SPSS and SAS users. 4th ed. Chicago: SPSS Inc.; 2007.Google Scholar
- Lobo SM. Sequential C-reactive protein measurements in patients with serious infections: does it help? Crit Care. 2012;16:130–1.View ArticlePubMedPubMed CentralGoogle Scholar
- Mohamed NM, Magzoub MSM, Osman AA, Abdalla NM. Clinical and epidemiological study on inflammatory polyneuropathy (Guillain-Barré syndrome) among Sudanese cases. Int J Clin Med Res. 2016;3(1):1–5.Google Scholar
- Newswanger DL, Warren CR. Guillain Barré syndrome. Am Fam Physician. 2004;69(10):2405–10.PubMedGoogle Scholar
- Ortiz-Corredor F, Pena-Preciado M, Diaz-Ruitz J. Motor recovery after Guillain-Barré syndrome in childhood. Disabil Rehabil. 2007;29:883–9.View ArticlePubMedGoogle Scholar
- Parmar LD, Doshi V, Singh SK. Nerve conduction studies in Guillian Barré syndrome. Int J Neurol. 2013;16(1):1–14.Google Scholar
- Peaceman AM, Andrews WW, Thorp JM. Fetal fibronectin as a predictor of preterm birth in patients with symptoms: a multicenter trial. Am J Obstet Gynecol. 1997;177:13–8.View ArticlePubMedGoogle Scholar
- Rajabally YA, Uncini A. Outcome and its predictors in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 2012;83:711–8.View ArticlePubMedGoogle Scholar
- Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain–Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011;36:123–33.View ArticlePubMedPubMed CentralGoogle Scholar
- Sudulagunta SR, Sodalagunta MB, Sepehrar M, Khorram H, Raja SKB, Kothandapani S, Noroozpour Z, Sham MA, Prasad N, Sunny SP, Mohammed MD, Gangadharappa R, Sudarshan RN. Guillain –Barré syndrome: clinical profile and management. GMS. 2015;13:1612–3174.Google Scholar
- Szalai AJ. C-reactive protein and autoimmune disease. Facts and conjectures. Clin Dev Immunol. 2004;11:221–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Uncini A, Kuwabara S. Electrodiagnostic criteria for Guillain-Barre syndrome: a critical revision and the need for an update. J Int Fed Clin Neurophysiol. 2012;123(8):1487–95.View ArticleGoogle Scholar
- Vaishnavi C, Kapoor P, Behura C, Singh SK, Prabhakar S. C-reactive protein in patients with Guillain Barre syndrome. Indian J Path Microbiol. 2014;57(1):51–4.View ArticleGoogle Scholar
- Walling AD, Dickson G. Guillain-Barre syndrome. Am Fam Physician. 2013;87(3):191–7.PubMedGoogle Scholar
- Willison HJ. The immunobiology of Guillain–Barré syndromes. J Peripher Nerv Syst. 2005;10:94–112.View ArticlePubMedGoogle Scholar
- Yu RK, Usuki S, Ariga T. Ganglioside molecular mimicry and its pathological roles in Guillain Barré syndrome and related diseases. Infect Immun. 2006;74:6517–27.View ArticlePubMedPubMed CentralGoogle Scholar
- Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med. 2012;366:2294–5.View ArticlePubMedGoogle Scholar